 WALTHAM, Mass., Feb. 10, 2022 GLOBE NEWSWIRE -- TScan Therapeutics, Inc. Nasdaq: TCRX, a biopharmaceutical company focused on the development of T-cell receptor TCR engineered T cell therapies TCR-T for the treatment of patients with cancer, today announced that the Company will present virtually at the 11th Annual SVB Leerink Global Healthcare Conference on Friday, February 18, 2022, at 12:00 p.m. Eastern Time. 